Compounds for modulating T-cells

Details Compounds for modulating T-cells Compounds for modulating T-cells

2008-04-11

2011-10-18

Lundgren, Jeffrey S (Department: 1629)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S228500, C514S264100, C514S353000, C514S339000, C514S217000

Reexamination Certificate

active

08039505

ABSTRACT:
Disclosed are compounds and compositions that modulate T-cells. Such compounds can be used to treat T-cell mediated disease like T-ALL, rheumatoid arthritis, multiple sclerosis, and graft-vs-host disease (GvHD), to name but a few. The compounds have a general structure as shown in Formula I.in-line-formulae description="In-line Formulae" end="lead"?Ar1-L-Ar2  Iin-line-formulae description="In-line Formulae" end="tail"?wherein Ar1and Ar2, are independent of one another, a substituted aryl, unsubstituted aryl, substituted heteroaryl, or unsubstituted heteroaryl; and L is a bond or a linker spanning two, three, four, or five atoms.

REFERENCES:
patent: 2005/0119177 (2005-06-01), Bar-Or et al.
Autoimmune diseases document, 2005, retrieved from the web on Jun. 21, 2010, URL: http://web.archive.org/web/20051202040221/http://www.labtestsonline.org.
Bowman, CME Journal, Jan. 15, 1981, vol. 124, pp. 129-142.
Ackermann et al., “Zebrafish: a genetic model for vertebrate organogenesis and human disorders,”Front Biosci8:d1227-1253 (2003).
Aster, “Deregulated NOTCH signaling in acute T-cell lymphoblastic leukemia/lymphoma: new insights, questions, and opportunities,”Int J Hematol82:295-301 (2005).
Bennett et al., “Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura,”Blood107:2639-2642 (2006).
Berube et al., “Apoptosis caused by p53-induced protein with death domain (PIDD) depends on the death adapter protein RAIDD,”Proc Natl Acad Sci U S A102:14314-14320 (2005).
Chhabra et al., “Activation-induced cell death of human melanoma specific cytotoxic T lymphocytes is mediated by apoptosis-inducing factor,”Eur J Immunol36:3167-3174 (2006).
Chipuk et al., “Dissecting p53-dependent apoptosis,”Cell Death Differ13:994-1002 (2006).
Clift et al., “Marrow transplantation for CML: the Seattle experience,”Bone Marrow Transplant17 Suppl 3:S1-3 (1996).
Cvetkovic et al., “Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia,”Drugs66:791-820 (2006).
Druker et al., “Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia,”N Engl J Med355:2408-2417 (2006).
Druker et al., “Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells,”Nat Med2:561-566 (1996).
Esteve et al., “Rho-regulated signals induce apoptosis in vitro and in vivo by a p53-independent, but Bcl2 dependent pathway,”Oncogene17:1855-1869 (1998).
Goldberg et al., “Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience,”J Clin Oncol21:3616-3622 (2003).
Gozuacik et al., “Autophagy and cell death,”Curr Top Dev Biol78:217-245 (2007).
Grabher et al., “Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia,”Nat Rev Cancer6:347-359 (2006).
Guo et al., “β-Catenin stabilization stalls the transition from Double-Positive to Single Positive stage and predisposes thymocytes to malignant transformation,”Blood(2007).
Hatanaka et al., “Photoaffinity labeling in drug discovery and developments: chemical gateway for entering proteomic frontier,”Curr Top Med Chem2:271-288 (2002).
Heidel et al., “Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia,”Thromb Haemost97:228-233 (2007).
Holler et al., “Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule,”Nat Immunol1:489-495 (2000).
Jaattela et al., “Caspase-independent cell death in T lymphocytes,”Nat Immunol4:416-423 (2003).
Langenau et al., “In vivo tracking of T cell development, ablation, and engraftment in transgenic zebrafish,”Proc Natl Acad Sci U S A101:7369-7374 (2004).
Langenau et al., “Suppression of apoptosis by bcl-2 overexpression in lymphoid cells of transgenic zebrafish,”Blood105:3278-3285 (2005).
Langenau et al., “Myc-induced T cell leukemia in transgenic zebrafish,”Science299:887-890 (2003).
Lin et al., “Pidd, a new death-domain-containing protein, is induced by p53 and promotes apoptosis,”Nat Genet26:122-127 (2000).
Murphey et al., “A chemical genetic screen for cell cycle inhibitors in zebrafish embryos,”Chem Biol Drug Des68:213-219 (2006).
Nesbit et al., “Chemotherapy for induction of remission of childhood acute myeloid leukemia followed by marrow transplantation or multiagent chemotherapy: a report from the Childrens Cancer Group,”J Clin Oncol12:127-135 (1994).
Newton et al., “Effects of a dominant interfering mutant of FADD on signal transduction in activated T cells,”Curr Biol11:273-276 (2001).
O'Connor et al., “CD95 (Fas/APO-1) and p53 signal apoptosis independently in diverse cell types,”Cancer Res60:1217-1220 (2000).
Oeffinger et al., “Chronic health conditions in adult survivors of childhood cancer,”N Engl J Med355:1572-1582 (2006).
Peterson et al., “Small molecule developmental screens reveal the logic and timing of vertebrate development,”Proc Natl Acad Sci U S A97:12965-12969 (2000).
Peterson et al., “Chemical suppression of a genetic mutation in a zebrafish model of aortic coarctation,”Nat Biotechnol22:595-599 (2004).
Randolph, “Acute promyelocytic leukemia (AML-M3)—Part 1: Pathophysiology, clinical diagnosis, and differentiation therapy,”Clin Lab Sci13:98-105 (2000).
Randolph, “Acute promyelocytic leukemia (AML-M3)—Part 2: Molecular defect, DNA diagnosis, and proposed models of leukemogenesis and differentiation therapy,”Clin Lab Sci13:106-116 (2000).
Reiter et al., “Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86,”Blood84:3122-3133 (1994).
Schmitt et al., “Dissecting p53 tumor suppressor functions in vivo,”Cancer Cell1:289-298 (2002).
Seddon et al., “TCR signals mediated by Src family kinases are essential for the survival of naive T cells,”J Immunol169:2997-3005 (2002).
Shepard et al., “A zebrafish bmyb mutation causes genome instability and increased cancer susceptibility,”Proc Natl Acad Sci U S A102:13194-13199 (2005).
Spring, “Chemical genetics to chemical genomics: small molecules offer big insights,”Chem Soc Rev34:472-482 (2005).
Stegmaier et al., “Gefitinib induces myeloid differentiation of acute myeloid leukemia,”Blood106:2841-2848 (2005).
Stern et al., “Small molecules that delay S phase suppress a zebrafish bmyb mutant,”Nat Chem Biol1:366-370 (2005).
Strasser et al., “DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2,”Cell79:329-339 (1994).
Tejeda et al., “Growth inhibitory effect of the somatostatin structural derivative (TT-232) on leukemia models,”Anticancer Res25:325-330 (2005).
Tolomeo et al., “Drug resistance and apoptosis in cancer treatment: development of new apoptosis-inducing agents active in drug resistant malignancies,”Curr Med Chem Anticancer Agents2:387-401 (2002).
Trede et al., “The use of zebrafish to understand immunity,”Immunity20:367-379 (2004).
Trede et al., “Organ development in zebrafish linked to network of coregulated splicing factors,”Proc. Natl. Acad. Sci. in press (2007).
Trede N., “Modeling and treating immune-mediated diseases using a transgenic line of zebrafish,” presented Apr. 8, 2006 at Thymoz Meeting International Workshop on T Lymphocytes, Heron Island, Australia (abstract).
Wahl

Affiliated with

Also associated with

Rating

Compounds for modulating T-cells does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds for modulating T-cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds for modulating T-cells will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4252815